Harmonizing scientific innovation, patient care and regulation in advanced therapies: a podcast with Patrice Faloye

00:06 Kadeja Johnson: Hi, I’m Kadeja, a digital editor of RegMedNet and today we’re joined by Patrice Faloye, who is a professional in regulatory affairs. Before we start, please would you mind introducing yourself and telling us a little bit about your experience as a regulatory affairs professional?

00:23 Patrice Faloye: Yes, of course. I’m Patrice Faloye, a regulatory affairs professional with over 18 years of experience across small molecules, biologics and more recently, RNA-based therapies. I’ve had the privilege of working across both the pharmaceutical industry and in recent years within biotech, supporting innovative and complex development programs. My experience spans early development through to mid and late stage programs, as well as full lifecycle management. My focus has primarily been on regulatory strategy, which involves shaping global development plans, leading marketing authorization, and clinical trial applications, as well as post-approval activities, which includes variations and renewals. I’ve had the opportunity to work across multiple regions in terms of the regulatory aspects, so that includes US, EU, UK, and international markets, which includes Middle East, North Africa, Latin America, APAC (Asia-Pacific), and Central Eastern Europe and Russia. Alongside my work in regulatory affairs, I’m passionate about mentoring undergraduates, recent graduates and career pivoters seeking to build or transition into the bio-pharmaceutical industry.

01:36 Kadeja Johnson: Thank you so much for giving us an introduction of yourself and your extensive experience as a professional, as well as your mentorship. It’s amazing to hear. Regenerative medicine is a rapidly evolving field. What are some of the unique regulatory challenges you’ve encountered when working with regenerative therapies, and how do they differ from those in small molecules or biologics?

01:55 Patrice Faloye: Before I delve into the question, I just want to baseline what regenerative medicine is for any new listeners, and I’ll go into some of the regulatory challenges. So, regenerative medicine is essentially about addressing the root cause of disease rather than simply managing symptoms. Instead of prescribing a medicine that someone takes daily to control a condition, we’re looking at ways to repair, replace, or regenerate damaged cells, tissues, or even genes. This may involve stem cells, gene therapies, or RNA-based treatments that instruct the body to produce what’s missing. So in more simple terms, it’s about helping the body restore normal function, and in some cases, potentially offering long-lasting or even one-time treatments. And that’s what makes it such a transformative area of medicine. You can see that things have really evolved within medicine and have come a long way.

So from a regulatory perspective, that ambition really brings complexity. Now, one of the biggest added complexities is that many regenerative therapies target rare or ultra-rare diseases, and in these areas you often don’t have the luxury of precedence and I will expand on that. So for small molecules, there’s usually established guidance, regulatory guidance. There are validated clinical endpoints in clinical trials and, you know, there are prior approvals which we can use to benchmark against. However, in rare regenerative therapies, sometimes none of these exist. Clear regulatory guidelines are important because they set defined expectations for evidence, quality and safety. Established clinical endpoints matter because they provide an agreed, measurable way to demonstrate meaningful patient benefit and prior approvals are valuable because they offer regulatory presidents a sense of what level of data and evidence regulators may consider acceptable. When I refer to regulators, I’m referring to competent authorities that are based around the world. So, for example, we may have heard of the US [Food and Drug Administration] that’s based in the US.

Europe has EMA, European Medicines Agency, and the UK, where we’re based, has the MHRA (Medicines and Healthcare products Regulatory Agency). So when those elements are missing, these key elements, you’re essentially building the roadmap in real time. That’s why early scientific advice and continuous dialogue with regulators become critical in the development of these medicines. Another major challenge is defining what clinical benefit actually means. Now, in many rare genetic or degenerative diseases, we don’t fully understand how the condition naturally progresses over time. There may be limited natural history data, no validated surrogate endpoints, and sometimes no established standard use of care.

So the fundamental question becomes, how do we prove this therapy is making a meaningful difference? Is it success measured by survival, by slowing disease progression, by looking at biomarkers, or a tangible functional improvement in a patient’s daily life? When there’s no established benchmark, an entirely new clinical endpoint may need to be proposed. So these endpoints must be scientifically sound, clinically meaningful to patients, and acceptable to regulators. Again, this goes back to the necessity of early and ongoing dialogue with health authorities.

Another aspect is small patient populations. Now, in rare diseases, patient numbers are inherently limited. That means clinical trial recruitment may take longer, trials are smaller, and the level of statistical certainty you typically expect from large randomized studies may not be achievable. There just may not be enough patients worldwide to run a traditional large-scale trial. So the development strategy has to balance scientific rigor with practical reality, ensuring that the data is robust, credible, even when patient numbers are small. So as a result, development programs often rely on more flexible approaches, such as adaptive clinical trials, single-arm studies, or the use of natural history and real-world data as contextual evidence.

But these need to be carefully justified to regulators, and they will expect a clear explanation of why the design is appropriate, how bias is controlled, and how the data will still provide reliable evidence of safety and efficacy. Another aspect I would like to touch on is patient advocacy. This plays a central role in clinical development. They help define meaningful outcomes, shape trial feasibility and inform benefit-risk discussions. Regulators increasingly value that patient voice, which is incorporated in a scientifically robust way. And that leads to another defining feature, long-term follow-up. So, because some regenerative therapies may have lasting biological effects, regulators often require safety monitoring for many years. So this can be 5, 10, or even 15 years post-treatment. And that’s very different from a typical small molecule development program. So overall, regenerative medicine is exciting precisely because it challenges traditional models. With small molecules, you’re often working with more established systems. With regenerative therapies, particularly in rare diseases, you’re helping to shape the system while ensuring scientific rigor, patient safety and long-term sustainability. And that’s why the balance, what makes regulatory affairs in this space both demanding and incredibly impactful, and truly imperative from the very beginning of development conversations, not as an afterthought, but as a strategic driver of success.

07:31 Kadeja Johnson: Thank you so much for giving us a deep dive into it, and for also reintroducing to us what regenerative medicine is. I think for a lot of people, this is a new concept for them. So hearing what it is, and how it affects patients, and the new trial data that’s coming out. And also, as you mentioned, the different endpoints that people must consider as to what makes a therapy successful, and also the patient advocacy side of it. That’s so important to mention. So thank you for explaining that.

08:00 Kadeja Johnson: So you’ve recently been in RNA therapeutics, and RNA-based therapies are becoming increasingly prominent in regenerative medicine. From a regulatory perspective, what are the most critical considerations when developing RNA therapeutics for clinical use?

08:17 Patrice Faloye: Yeah, so when developing RNA therapeutics for clinical use, a few regulatory pillars that consistently matter, and which are sought by regulatory authorities.

So first, we look at how the product is made. With RNA therapies, the product is not just the genetic code; it’s the exact RNA sequence. So we’re looking at the chemical modifications added to stabilize it, the backbone chemistry that changes how it behaves in the body, the formulation and often the delivery system. So with RNA therapies, the manufacturing strategy is therefore central to approval. Small changes can really alter safety, biodistribution − that’s how the product is distributed throughout the body − and also the product’s activity. So regulators, as I mentioned earlier, like the FDA, EMA, MHRA, will carefully check that the therapy is exactly what an organization says it is. You know, they’re looking at ensuring that it’s free from harmful impurities, it works how it’s intended to, and is made the same way every time. So it’s consistent, it’s repeatable − the manufacturing process − and that the product remains safe and effective as long as it’s stored.

Another aspect is, how does the therapy work? You know, RNA therapies are considered as targeted therapies, as they are designed to act very precisely, often at a specific genetic target. And because of that, regulators expect to see a clear connection between how the therapy works at a molecular level, the biological changes you can measure in the body, as I mentioned earlier about biomarkers, and the actual clinical benefit for patients. This has to be demonstrated in patients, and you know, we look at the therapy, that the therapy is triggering the intended biological effect and that this effect translates into meaningful outcomes. Biomarkers are often essential in demonstrating this link, especially in early development of rare diseases where large trials may not be feasible.

Another aspect that is looked at is the class-specific safety considerations. RNA products can trigger predictable regulatory questions around this. You know, they look at is the therapy unintentionally activating the immune system, so any immune activation, whether there are any off-target effects, you know, or side effects, consider the side effects. Where does the therapy travel to in the body, and where does it accumulate? And how long does the effect last? Is it temporary or is it prolonged? So, the non-clinical program will need to address these questions up front by choosing the right laboratory and animal models, generating the appropriate safety data, and clearly explaining and justifying the proposed starting dose and dosing schedule that will be used in the clinical trial.

Another aspect is the clinical trial design. Many RNA therapies target serious or genetic conditions where patient numbers are often small. That typically means working with smaller study populations, relying more heavily on biomarker-driven endpoints, and sometimes using adaptive trial designs to make development more efficient without compromising scientific robustness. Because of this complexity, early scientific advice from regulators is essential to agree up front what meaningful clinical benefit looks like, how this will be measured, and whether the proposed clinical trial design is robust enough to support future marketing authorization approval. And when I refer to marketing authorization approval, for people that, you know, are not aware, that’s basically the license to say this product is approved, it meets the standards that is required. Also, as many RNA therapies target serious conditions with a high unmet need, access to patient sponsors may seek accelerated and orphan pathways. So, many regulators or regulatory authorities across the world will have these pathways which are available to accelerate approval. In the US, and in the EU, we have Orphan Drug Designation. In Europe, we also have PRIME designation and in the US, we have other designations such as Fast Track, Breakthrough Therapy and Accelerated Approval [Program].

Successful RNA development requires early regulator engagement and strategic discussions and alignment. So, it’s really important that, you know, it’s not simply about compliance, but it’s about shaping the pathway, the regulatory pathway, that turns innovative science into safe, accessible medicines.

12:46 Kadeja Johnson: Thank you so much for explaining that and for breaking it down for us and for also providing so many examples. I think that’s really helpful. With your extensive experience in regulatory affairs, what’s one key lesson or piece of advice you would offer for those entering the field, particularly in the context of regenerative medicine?

13:07 Patrice Faloye: One key advice or key lesson I would share is that start regulatory thinking early, really early in development, where you’re working with cell therapies, gene therapies, or RNA-based treatments. The science moves really quickly. It’s constantly evolving. It’s quite dynamic. But regulators still need clear, robust evidence around safety, quality and clinical benefit. You know, if you wait quite late in the development of the program to think strategically about the regulatory pathway, your endpoint, or your manufacturing controls, you’re really behind. So for those entering the field, I’d say don’t see regulatory affairs as a final checkpoint or a tick box or, you know, looking at pulling documents together, because I feel like a lot of people think it’s very much a ‘PDF’ exercise, and it really isn’t. Regulatory affairs is more of a strategic partner from day one. It’s really important that the regulatory affairs counterparts are really pulled into discussions, you know, understand the science deeply, ask the right questions early, engage with health authorities proactively, and always think ahead, not just to approval, but looking at the real-world access for patients. You know, these therapies are often for serious or rare conditions. So that means that regulatory professionals are, you know, as I mentioned, not just about managing documents, but really here to shape how innovation safely reaches patients.

14:33 Kadeja Johnson: I love that. I love how you mentioned that it’s not just about approval, it’s about how these medicines can safely reach patients. And it’s such a key and vital role that you play in this. Which leads me to the next question: what are some critical processes or considerations that developers often overlook during the mid-to-late stages of therapeutic development and how can addressing these early improve the chances of regulatory and commercial success?

15:01 Patrice Faloye: Yeah, so this is a really important question, because many challenges and, you know, later development actually start much earlier.

So one area that often is overlooked is early alignment on what clinical success really means. It’s not enough just for therapy to show statistical significance. You know, regulators and peers will ask, “Is this clinically meaningful? Does it change patient outcomes in a real way?” If that isn’t clearly defined early, you risk generating data that doesn’t fully support approval or reimbursement. And that happens in many development programs.

I also see teams underestimate the importance of global regulatory strategy, you know, not thinking about just considering one particular region and not the entire market that they could fulfill. And when I’m discussing different regions, I’m talking about the US, the EU, UK, Japan, you know, they all have different regulatory expectations. So if you don’t plan with a global lens, you may end up repeating studies or facing unexpected questions late in development, which could be anticipated.

And finally, market access and commercial reality, you know, really need to think early about cost reimbursement and real-world evidence. Approval alone does not guarantee patient access, unfortunately. You know, addressing these early improves your chances because you’re reducing risk proactively. You’re not just asking, “Can we get approved”? You’re asking, can this therapy be approved, reimbursed, scaled, and truly adopted? Now that’s the difference between the regulatory success and the real-world impact.

16:31 Kadeja Johnson: Amazing. Thank you. And yes, as you mentioned, just because something gets approved doesn’t mean that patients will be able to access them. And I think we’re seeing that more recently, as a lot of these medicines and approved medicines are entering the commercial space with a lot of patients who really need them, and unfortunately can’t afford them

16:50 Kadeja Johnson: So, as regenerative medicine continues to advance, how do you envision the role of regulatory affairs professionals evolving to meet the demands of this innovative field?

17:00 Patrice Faloye: I think this is such an important question. Regulatory affairs is such a highly strategic partner within the field. I feel it’s a foundational role in understanding science, deeply challenging, shaping and translating it clearly for health authorities. So, you know, it’s very vital to have this very early engagement. You know, I see us becoming much stronger bridges with it between R&D, manufacturing, commercial teams and regulators. I mean, we are a strong bridge, but I think it will become even more kind of stronger, more engaged, you know, with earlier conversations, more iterative and more collaborative than ever before. And not only between the cross-functional teams, but I’m also referring here to, you know, within small biotech, these bridges will connect the C-suite and investors. You know, I’m hoping to see more chief regulatory officer positions in the C-suite. I have not seen many so far, only a few roles and a few people in those positions. So I feel that’s important to ensure conversations kind of happening in the beginning and up that higher level.

There’s also a shift to a proactive engagement, more scientific advice meetings, more parallel consultation with regulators and HTA bodies, you know, more of that global coordination, as I mentioned earlier in the previous response, that previous question. I mean, it is happening now, but I feel that as we go more global, these conversations will be happening a lot more in the future. So ultimately the role will continue to evolve, you know, becoming a much more stronger strategic partner. And that’s, in my view, makes the role even more impactful.

18:37 Kadeja Johnson: It certainly will. And I can definitely see those conversations beginning to change and the involvement beginning to adapt to what’s happening now. It’s a strive, I think, on both parts to want to do more for patients as well as to advance the science across different entities. So thank you so much.

18:55 Kadeja Johnson: And finally, you are passionate, as you mentioned, about mentoring individuals who want to grow or transition into the biopharmaceutical industry. What drives this passion and how has mentorship shaped your own career journey?

19:10 Patrice Faloye: So mentorship is deeply personal to me. I actually stumbled into regulatory affairs. A university friend mentioned the role to me. It was never presented as a career option degree. And I’m sure like many others, you know, many other people probably didn’t realize that this role existed as a profession. So along the way, I’ve been fortunate to build strong friendships within the profession. You know, people I can lean on, ask advice from and bounce ideas off. You know, people that I, as I mentioned earlier, I’ve been in regulatory affairs for over 18 years and some of these people that I’ve met who are colleagues, have become long-lasting friends. And we, you know, we still discuss things to this day and call upon each other for any questions that we may potentially have. So that support network has been really invaluable in, you know, developing my role as a professional.

University teaches you the science, you know, it doesn’t always prepare us for the realities of navigating a career. So, you know, things like the uncertainty, the strategic decisions, the setbacks, the politics that happen within working, within any profession, really. So, you know, mentorship, what drives my passion now is knowing how transformative the right guidance can be, you know, this industry can feel complex and opaque from the outside. Mentorship really demystifies that; it builds confidence, it accelerates growth. So for me, mentoring isn’t just about career progression, it’s about legacies, about opening doors a little wider than they were for me. So, and that’s why I find it incredibly rewarding.

20:46 Kadeja Johnson: Thank you so much for sharing and for providing that insight. Yeah, I was in the same boat when I was in university. I did biomedical science, and it wasn’t certainly clear how many different roles you could enter outside of, like wanting to be in the lab and, you know, the different parts that play into it. So it’s incredible that you are nurturing that space for others who were in the same position you were, you know, a few years ago. So thank you so much for doing this podcast with us and for sharing your insights. They’ve truly been valuable and I’ve enjoyed the conversation that we’ve had today.

21:22 Kadeja Johnson: Yeah, any last thoughts or any remaining thoughts you’d like to add?

21:26 Patrice Faloye: Yeah, I, you know, I’ve been in regulatory affairs for so many years in this profession, it’s constantly evolving, you know, you can be in the profession for so many years and tomorrow there’s a new pharmaceutical regulation, which is actually happening at this very moment. So I think for anyone that’s interested in regulatory affairs, you know, go on LinkedIn, find other people that are within the industry, connect with them, ask questions, you know, connect with me. I, if you have any questions, reach out and I’d be openly willing to answer them.

21:54 Kadeja Johnson: Thank you so much.

21:56 Patrice Faloye: Thank you.